SESSION TITLE: COPD Comorbidity Posters
SESSION TYPE: Poster Presentations
PRESENTED ON: Saturday, March 22, 2014 at 01:15 PM - 02:15 PM
PURPOSE: The Baseline (BDI) and Transition Dyspnea Index (TDI) are interview-based multidimensional instruments to assess breathlessness in patients with COPD. However, BDI/TDI interviewer process may introduce bias in the interpretation, leading to more variability in results. Innovative self-administered computerized (SAC) versions of the BDI/TDI were developed and validated for the BLAZE study which allows patients to provide direct ratings of breathlessness based on activities of daily living.
METHODS: A standardized methodology (MAPI guidelines) was followed to translate the SAC BDI/TDI and 45 COPD patients participated in tests for its acceptability. In-depth interviews to evaluate comprehension and acceptability using laptop computers were conducted in Dutch, Danish, English, Flemish, French, German, and Spanish (5 patients in each language).
RESULTS: Most patients liked the SAC versions; only 4 patients had problems using computer mouse to click on the right answer for the BDI. The items were understood with no difficulties; most challenging issue was the comprehension of the equivalents of "Baseline" and "Transition". 42% of the patients had difficulties with the instructions to select answers on the TDI. These difficulties were resolved after patients answered the practice question designed to help the patients become familiar with clicking in a box for BDI and using the up-and-down arrows for TDI.
CONCLUSIONS: The SAC-BDI/TDI has the potential to advance our knowledge of patient-reported outcomes and be a beneficial tool for assessing breathlessness related to activities of daily living in COPD patients.
CLINICAL IMPLICATIONS: The SAC-BDI/TDI has the potential to be a beneficial tool for assessing breathlessness in COPD patients, by relying on the direct patient-reported ratings of dyspnea.
DISCLOSURE: Anthony D'Urzo: Consultant fee, speaker bureau, advisory committee, etc.: AD has received research, consulting and lecturing fees from GlaxoSmithkline, Sepracor, Schering Plough, Altana, Methapharma, AstraZeneca, ONO pharma, Merck Canada, Forest Laboratories, Novartis Canada/USA, Boehringer Ingelheim (Canada) Ltd, Pfizer Canada, SkyePharma, and KOS Pharmaceuticals. Donald Mahler: Consultant fee, speaker bureau, advisory committee, etc.: The presenting author is a consultant for GlaxoSmithKline, Novartis, and Sunovion, and have served on Advisory Boards for Boehringer Ingelheim, GlaxoSmithKline, Novartis, Pearl, and Sunovion, The C linical Trials Office at Dartmouth-Hitchcock Medical C enter (DHMC ) is currently receiving grants for clinical trials from Boehringer Ingelheim, Novartis, and Sunovion; Donald A. Mahler, M.D. is the DHMC principal investigator for these studies. Tracy White: Employee: Novartis employee Vijay Alagappan: Employee: Novartis employee Hungta Chen: Employee: Novartis employee Karoly Kulich: Employee: Novartis employee Nicola Gallagher: Employee: Novartis employee Donald Banerji: Employee: Novartis employee The following authors have nothing to disclose: Vanessa Brunel
Clinical trial results of QVA149, combination of two approved products indacaterol and glycopyrronium, will be presented, QVA 149 is in the late stage phase 3 trials prior to approval